IDDI
DATA WITH PURPOSE

See What Others Don't

The Highest Standard in Ophthalmology-Focused Clinical Data Science

Ophthalmology trials seem straightforward, until enrollment, endpoint noise, and regulatory expectations start eroding timelines and data quality. A surface-level approach isn't enough. You must look deeper with strategic study design, biostatistical rigor, and a laser focus on helping patients. See what others don't with IDDI.

52% of patients who enter screening in retina trials fail to qualify.[1]

Ophthalmic imaging endpoints often lose almost **40% of scans** to quality issues.[2]

Common functional endpoints have up to **50% variability**.[3]

Reduce Risk, Improve Outcomes

With a 35+ year legacy and experience supporting 180+ ophthalmology trials across retinal diseases, glaucoma, rare diseases, and MedTech, IDDI helps you avoid costly missteps and paves the way for more effective ophthalmology treatments.

Common Ophthalmology Pitfalls	IDDI's Solutions
Unrealistic or underinformed trial design, leading to delays and wasted resources.	Biostatistics-first model informs smarter trial designs and sample size calculations.
Primary endpoints that don't reflect real-world or regulatory relevance, increasing the risk of trial failure or non-approval.	Ideal endpoint selection using robust statistical rationale and ophthalmology-specific insights.
Insufficient communication between departments or siloed study operations, causing inefficiencies and errors.	Cross-functional team executes with uncompromising excellence for faster, more coordinated operations.
Difficult patient recruitment due to rare diseases and narrow eligibility, causing enrollment delays, underpowered studies, and increased costs.	Feasibility-driven design and experience from 180+ ophthalmology trials support more realistic planning.
Lack of statistical insight into variability and design risk, leading to under/overestimation of treatment effects and trial failure.	Advanced statistical methodologies account for functional endpoint variability and minimize risk.

When it comes to your trial's most critical asset, why would you trust anyone but the best? Partner with IDDI for the highest standard in ophthalmology-focused clinical data science.

Start Now

References

[1] Hasan, N., Mehrotra, K., Danzig, C., et al. Screen Failures in Clinical Trials in Retina. Ophthalmology Retina. November 2024.

[2] Lujan, B.J., Calhoun, C.T., Glassman, A.R., et al. Optical Coherence Tomography Angiography Quality Across Three Multicenter Clinical Studies of Diabetic Retinopathy. Transl Vis Sci Technol. March 2021.

[3] Rabiolo, A., Morales, E., Afifi, A., et al. Quantification of Visual Field Variability in Glaucoma: Implications for Visual Field Prediction and Modeling. TVST. October 2019.

IDDI
DATA WITH PURPOSE

IDDI is a trusted clinical data science partner. With 35+ years of research-driven experience, we combine therapeutic expertise, biostatistical leadership, and regulatory insight to mitigate risk from design to registration and beyond. We deliver uncompromising excellence in biostatistics, strategic consulting, clinical data management, IDMCs, and supporting eClinical technologies, because when every data point represents a patient, perfection is the only option. Learn more at IDDI.com.

iddi.com | info@iddi.com